肾癌:毒性管理、症状控制与姑息治疗
本文讨论接受靶向治疗和免疫治疗的肾癌患者常见毒性及症状问题,并界定姑息治疗的组成部分及其获益。文中的推荐来自肿瘤护理学会、ASCO、美国国家综合癌症网络和癌症免疫治疗学会等指南的源文件。作者认为可根据需要调整和个体化管理,以期为患者及其家庭提供最佳结局。
要点
- 提供者需了解肾癌各种治疗相关的潜在不良反应。
- 应纳入姑息治疗策略以管理症状、改善生活质量并支持患者及家庭。
- 推荐来自肿瘤护理学会、ASCO、NCCN和癌症免疫治疗学会等指南源文件。
核心结论
- 作者认为可根据需要调整和个体化管理,以期为患者及其家庭提供最佳结局。
研究设计与样本
- 本文为综述,讨论接受靶向治疗和免疫治疗的肾癌患者的一般毒性和症状问题,并界定姑息治疗的组成部分及其获益。
关键数值与推荐
- 文中的推荐来自肿瘤护理学会、ASCO、美国国家综合癌症网络和癌症免疫治疗学会等指南的源文件。
临床怎么用
- 提供者不仅需了解疾病,还需了解各种治疗相关的潜在不良反应。
- 应纳入姑息治疗策略以管理症状、改善生活质量,并在疾病全程支持患者及其家庭。
- 作者认为可根据需要调整和个体化管理,以期为患者及其家庭提供最佳结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The challenges of managing the toxicities associated with the current armamentarium to combat kidney cancer continue to grow. It is therefore paramount for providers to not only have knowledge of the disease, but to also have an understanding of the potential adverse effects associated with the various treatments. In addition, it is important to incorporate palliative care strategies to help manage symptoms, improve quality of life, and support patients and their families throughout the continuum of the disease. This article will discuss the general toxicities and symptomatic issues encountered in patients with kidney cancer who are receiving targeted therapies and immunotherapies. It will also define the components of palliative care and its benefits. The recommendations in this article are from source documentation noted in various guidelines of the Oncology Nursing Society, ASCO, the National Comprehensive Cancer Network, and the Society for Immunotherapy of Cancer. We feel it is appropriate to modify and individualize management as deemed necessary to provide the best outcome for patients and their families.
引用
- Sinibaldi VJ, Pratz CF, Yankulina O, et al. Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. J Clin Oncol. 2018. PMID: 30372391. doi:10.1200/JCO.2018.79.0188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。